France

On September 6, 2025, the specifications of the call for projects "Third places for MedTech experimentation" were approved. This initiative is part of the France 2030 investment plan and aims to fund the creation of collaborative testing hubs within healthcare facilities to accelerate the development and market access of innovative medical devices, with a specific focus on surgical robotics and implantable medical devices.

On September 6, 2025, the Ministry of Labor, Health, Solidarity and Families authorized a two-year experiment on the reprocessing of certain single-use medical devices used in the cardiology field, including cardiac electrophysiology and mapping, cardiac ablation, angiography devices, and ultrasound catheters. The experiment aims to assess the technical feasibility, safety, economic impact, and environmental benefits of this practice, with a view to its permanent establishment and expansion. The experiment will start on January 1, 2026.

The French National Authority for Health (HAS) released new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the August 2025 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Four favourable opinions were issued concerning add-on reimbursement for medical devices in the cardiovascular, ENT, and neuromodulation fields.

In August 2025, the updated version of the intra-DRG list was published in France. One new device was registered in the neurovascular field (BOBBY balloon guide catheter). Another change concerned the renewal of the registration for one device.

On August 5, 2025, the Ministry of Labor, Health, Solidarity, and Families published the 2025 version of the List of Innovative Procedures Outside the Nomenclature (LAHN), which specifies tests funded under the innovative payment scheme for in-vitro diagnostics (RIHN). Tariffs for tests included in the LAHN were expected to decrease by 20% annually from January 1, 2025, except for those with a positive evaluation by the French National Authority for Health (HAS) in defined clinical indications. However, unlike previous edition, the 2025 LAHN does not specify tariffs. It introduces 14 new codes, which duplicate existing generic codes but are restricted to the clinical indications positively assessed by HAS. These new codes will be exempt from the annual tariff reduction.

On July 29, 2025, the French National Authority for Health (HAS) issued positive opinions on including targeted next-generation sequencing-based panels in certain clinical indications for patients with aminoacidopathy and acute leukaemia in the NABM Nomenclature for regular reimbursement. Currently, these tests are temporarily reimbursed within the innovative payment scheme (RIHN). These HAS assessments are performed by HAS as a part of the RIHN reform and ‘cleaning up’ the List of temporary covered tests.

The French National Authority for Health (HAS) released new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the July 2025 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Four favourable opinions were issued concerning add-on reimbursement for medical devices in the orthopedics and ENT fields.

On July 15, 2025, the Ministry of Labor, Health, Solidarity, and Families published the instruction on the application for coverage with evidence development programs for 2025-2026. The instruction details the specific fields of research, the application procedures, and the deadlines for different types of programs (PHRC, PRME, PREPS, PHRIP, and PRT).

On July 10, 2025, a decision of the National Union of Health Insurance Funds regarding the update of the CCAM Classification of Medical Procedures was published. The update includes the provisional registration of one procedure code for transrectal HIFU destruction of prostate lesions and changes to indications and billing notes for several existing codes. The update takes effect on September 1, 2025.

The French National Authority for Health (HAS) released new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the June 2025 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Seven favourable opinions were issued concerning add-on reimbursement for medical devices in the cardiovascular, peripheral vascular, and ophthalmology fields.

On June 18, 2025, a new version of the Nomenclature of Medical Biology Procedures (NABM 98) was released. Seven new codes were introduced.

On June 5, 2025, the French National Authority for Health (HAS) published its favorable opinion on the coverage of AI-assisted digitalized urine cytology using VisioCyt Bladder, an in-vitro diagnostic medical device, under the renewed Repository of Innovative Procedures outside the Nomenclature of Biology and Anatomocytopathology (RIHN) 2.0.